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Unrelated donor haemopoietic stem-cell transplantation: 
ATG or not?
Chronic graft-versus-host disease (GVHD) is a 
multisystemic syndrome involving tissue inflammation 
and fibrosis that shares many clinical manifestations 
with autoimmune diseases such as systemic lupus 
erythematous or systemic sclerosis.1 Despite being 
associated with lower relapse rates, chronic GVHD is the 
main cause of late mortality after unrelated allogeneic 
haemopoietic stem-cell transplantation. Furthermore, 
chronic GVHD has a large effect on quality of life.2 
Since the mid-1980s, the standard GVHD prophylaxis 
for patients transplanted following  myeloabaltive 
conditioning has consisted of the combination of 
ciclosporine (or tacrolimus) with a short course of 
methotrexate.3 This regimen has been relatively 
successful at preventing severe acute GVHD but largely 
failed to prevent chronic GVHD in patients receiving 
grafts from unrelated donors or in those given 
peripheral blood stem-cells rather than bone marrow.4 
Rabbit anti-thymocyte globulins (ATGs) are polyclonal 
immunoglobulins obtained from hyperimmune sera 
of rabbits immunised with the human Jurkat leukemic 
T-cell line (anti-T-lymphocyte globulin, ATLG) or human 
thymocytes (thymoglobuline).5 Five randomised studies 
have assessed the effect of ATLG or thymoglobuline on 
GVHD prevention in patients receiving bone marrow 
or peripheral blood stem-cells from unrelated donors, 
or peripheral blood stem-cells from HLA-identical 
siblings. Despite important differences in the setting 
of these five trials, all showed that ATG protected from 
severe chronic GVHD. Relapse and overall survival were 
not significantly affected by ATG in four of these trials, 
whereas preliminary data from the trial of Soiffer and 
colleagues6 show worse 2-year survival in patients 
in the ATLG group due to higher relapse-related 
mortality. There are no obvious explanations for these 
discrepancies besides that immunosuppression after 
grafting consisted of tacrolimus plus methotrexate in 
the study by Soiffer and colleagues and ciclosporine plus 
methotrexate in the other four trials.
Aside from the GITMO study (which was done in an 
era when matching standards for unrelated donor grafts 
were less stringent), randomised trials of ATGs have 
had a relatively short median follow-up (1–3 years). In 
The Lancet Haematology, Finke and colleagues7 report 
the final results of a randomised phase 3 multicentre 
trial (previously reported after a median follow-up 
of 2 years8) comparing standard GVHD prophylaxis 
with ciclosporine and methotrexate with or without 
additional ATLG (60 mg/kg total dose) in patients 
given grafts (mainly peripheral blood stem-cells) from 
unrelated donors. Median follow-up was 8·6 years. The 
main observations were that, at 8 years, the probability 
of being alive and free of immunosuppressive therapy 
was 11% (95% CI 5–18) in the non-ATLG group versus 
47% (37–57) in the ATLG group (p=0·0002), while severe 
GVHD-free and relapse-free survival (which serves as 
a measure of cure without ongoing morbidity) was 
13% (95% CI 7–21) in the non-ATLG group versus 34% 
(25–43) in the ATLG group (p=0·0003; figure 1). Relapse 
mortality was not increased by ATLG (adjusted HR 
1·03, 95% CI 0·61–1·76; p=0·90), which is reassuring 
regarding the long-term safety of ATLG. Finally, 8-year 
overall survival was 37% (27–47) in non-ATLG patients 
versus 49% (39–59) in ATLG patients (p=0·3). 
These findings are remarkable in several aspects. First, 
the study showed that only 11% of non-ATLG patients 
were alive and free of immunosuppressive therapy (a 
good marker for survival without ongoing severe chronic 
GVHD) 8 years after transplantation, which might seem 
insufficient. ATLG administration significantly improved 
this endpoint to 47%. Given the substantial effect of 
Figure 1: Major transplantation outcomes at 8 years
Blue circles=non-ATLG. Red squares=ATLG. Error bars show the 95% CIs. 
Ext-cGVHD=extensive chronic GVHD. NRM=non-relapse mortality. 
GRFS=GVHD-free and relapse-free survival. OS=overall survival. 
ATLG=anti-T-lymphocyte globulin.
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chronic GVHD treatment on quality-of-life, these data 
should be taken in consideration for decision-making 
and patient counselling. Second, this study shows 
the long-term safety ATLG administration before 
transplantation with an 8-year incidence of relapse-
related mortality similar in both groups and an overall 
survival at least as good in ATLG as in non-ATLG groups. 
However, the trial did not assess the effect of ATLG on 
long-term quality-of-life and other survivorship issues. 
Although long-term data reported by Finke and 
colleagues suggest that ATLG could be the standard 
of care for patients receiving peripheral blood stem-
cells from unrelated donors after myeloablative 
conditioning, it is unclear whether some subgroups 
of patients do not benefit or even could be harmed by 
ATLG administration. It is reassuring that no interactive 
effects between ATLG administration and disease status 
or stem-cell source could be detected in the study 
by Finke and colleagues, although the trial was not 
powered to adequately address these issues. Further, 
the trial included only patients receiving grafts after 
myeloablative conditioning and thus did not address 
the effect of ATG administration in patients who had 
reduced intensity conditioning allogeneic haemopoietic 
stem-cell transplantation, a transplantation approach 
that relies mainly on immune-mediated graft-versus-
tumour effects to eradicate leukaemia. Another 
important question is whether the same dose of ATG 
per kg should be used for all unrelated recipients of 
peripheral blood stem-cells or whether the dose should 
be individualised according to other factors affecting 
ATG pharmacokinetics such as absolute lymphocyte 
counts at the time of ATG administration.9 
Although long-term ATLG results reported by 
Finke and colleagues are impressive, several novel 
promising strategies for GVHD prophylaxis are under 
investigation.3,10 Further prospective randomised trials 
are needed to compare ATG with these strategies. 
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